Dan Xu, Ankith Nair, Charlie Sigston, Chau Ho, Jia Li, Daya Yang, Xinxue Liao, Wei Chen, Ming Kuang, Yanbing Li, Christopher Reid, Haipeng Xiao
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, liraglutide, semaglutide, albiglutide, and dulaglutide, are associated with a significantly 14% lower risk of MACE in patients with T2DM and a history of CV disease, and with a nonsignificantly 6% lower risk in patients without history of CV disease...
2022: Cardiovascular Therapeutics